Literature DB >> 21540415

Treatment for lupus, first in 50 years, offers modest benefits, hope to patients.

Mike Mitka.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21540415     DOI： 10.1001/jama.2011.548

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  11 in total

Review 1.  Belimumab: in systemic lupus erythematosus.

Authors:  Celeste B Burness; Paul L McCormack
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

2.  B lymphocyte stimulator levels in systemic lupus erythematosus: higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels.

Authors:  Lauren L Ritterhouse; Sherry R Crowe; Timothy B Niewold; Joan T Merrill; Virginia C Roberts; Amy B Dedeke; Barbara R Neas; Linda F Thompson; Joel M Guthridge; Judith A James
Journal:  Arthritis Rheum       Date:  2011-12

Review 3.  B-cell-depleting therapy in systemic lupus erythematosus.

Authors:  Manuel Ramos-Casals; Iñaki Sanz; Xavier Bosch; John H Stone; Munther A Khamashta
Journal:  Am J Med       Date:  2012-04       Impact factor: 4.965

4.  Amending HIV Drugs: A Novel Small-Molecule Approach To Target Lupus Anti-DNA Antibodies.

Authors:  Sonya VanPatten; Shan Sun; Mingzhu He; Kai Fan Cheng; Ahmad Altiti; Angelos Papatheodorou; Czeslawa Kowal; Venkatesh Jeganathan; James M Crawford; Ona Bloom; Bruce T Volpe; Christian Grant; Nathalie Meurice; Thomas R Coleman; Betty Diamond; Yousef Al-Abed
Journal:  J Med Chem       Date:  2016-09-20       Impact factor: 7.446

5.  Defining biological subsets in systemic lupus erythematosus: progress toward personalized therapy.

Authors:  Nailú Angélica Sinicato; Mariana Postal; Simone Appenzeller; Timothy B Niewold
Journal:  Pharmaceut Med       Date:  2017-01-25

6.  A pre-clinical quantitative model predicts the pharmacokinetics/pharmacodynamics of an anti-BDCA2 monoclonal antibody in humans.

Authors:  Konstantinos Biliouris; Ivan Nestorov; Himanshu Naik; David Dai; Guangqing Xiao; Qin Wang; Alex Pellerin; Dania Rabah; Lawrence J Lesko; Mirjam N Trame
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-10-30       Impact factor: 2.745

7.  New treatment options for lupus - a focus on belimumab.

Authors:  Laurent Chiche; Noémie Jourde; Guillemette Thomas; Nathalie Bardin; Charleric Bornet; Albert Darque; Julien Mancini
Journal:  Ther Clin Risk Manag       Date:  2012-01-26       Impact factor: 2.423

8.  Assessment of the Economic Impact of Belimumab for the Treatment of Systemic Lupus Erythematosus in the Italian Setting: A Cost-Effectiveness Analysis.

Authors:  Francesca Pierotti; Ilaria Palla; Maarten Treur; Lara Pippo; Giuseppe Turchetti
Journal:  PLoS One       Date:  2015-10-21       Impact factor: 3.240

9.  Patient perceptions and preferences of biologic therapies in SLE.

Authors:  S Sam Lim; Hong Kan; Bonnie F Pobiner; Gaobin Bao; Cristina Drenkard
Journal:  Lupus Sci Med       Date:  2019-08-12

Review 10.  I too, am America: a review of research on systemic lupus erythematosus in African-Americans.

Authors:  Edith M Williams; Larisa Bruner; Alyssa Adkins; Caroline Vrana; Ayaba Logan; Diane Kamen; James C Oates
Journal:  Lupus Sci Med       Date:  2016-08-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.